鈴木 健文 教授

精神神経薬理学の研究がメインですが、臨床に役に立つことをしよう、をモットーに幅広い領域に関する臨床研究を行っています。今後も臨床研究を進めつつ、精神疾患の病態解明に迫れるような研究にも関与していきたいと思います。以下に今までの仕事の一部を示しますが、興味のある方は医局にいらして頂ければ、PDFを差し上げます。

Howes OD, et al. Treatment-Resistant Schizophrenia: Treatment Response
and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines
on Diagnosis and Terminology. Am J Psychiatry. 2017 Mar
1;174(3):216-229.

Suzuki T. A further consideration on long-acting injectable versus
oral antipsychotics in the treatment of schizophrenia: a narrative
review and critical appraisal. Expert Opin Drug Deliv.
2016;13(2):253-64.

Iwata Y, et al. Effects of glutamate positive modulators on cognitive
deficits in schizophrenia: a systematic review and meta-analysis of
double-blind randomized controlled trials. Mol Psychiatry. 2015
Oct;20(10):1151-60.

Graff-Guerrero A, et al. Evaluation of Antipsychotic Dose Reduction in
Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor
Occupancy Study. JAMA Psychiatry. 2015 Sep;72(9):927-34.

Suzuki T, et al. Relationships between global assessment of
functioning and other rating scales in clinical trials for
schizophrenia. Psychiatry Res. 2015 Jun 30;227(2-3):265-9

Suzuki T, et al. Dopamine D₂/₃ occupancy of ziprasidone across a day:
a within-subject PET study. Psychopharmacology (Berl). 2013
Jul;228(1):43-51.

Suzuki T, et al. Defining treatment-resistant schizophrenia and
response to antipsychotics: a review and recommendation. Psychiatry
Res. 2012 May 15;197(1-2):1-6.

Suzuki T, et al. Novel rating scales for schizophrenia – Targeted
Inventory on Problems in Schizophrenia (TIP-Sz) and Functional
Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz).
Schizophr Res. 2008 Dec;106(2-3):328-36.

Suzuki T, et al. How effective is it to sequentially switch among
Olanzapine, Quetiapine and Risperidone?–A randomized, open-label
study of algorithm-based antipsychotic treatment to patients with
symptomatic schizophrenia in the real-world clinical setting.
Psychopharmacology (Berl). 2007 Dec;195(2):285-95.

Suzuki T, et al. Revising polypharmacy to a single antipsychotic
regimen for patients with chronic schizophrenia. Int J
Neuropsychopharmacol. 2004 Jun;7(2):133-42.